Aquestive Therapeutics (AQST) Operating Leases: 2020-2025
Historic Operating Leases for Aquestive Therapeutics (AQST) over the last 6 years, with Sep 2025 value amounting to $5.1 million.
- Aquestive Therapeutics' Operating Leases fell 8.62% to $5.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.1 million, marking a year-over-year decrease of 8.62%. This contributed to the annual value of $5.0 million for FY2024, which is 7.98% down from last year.
- According to the latest figures from Q3 2025, Aquestive Therapeutics' Operating Leases is $5.1 million, which was down 2.46% from $5.2 million recorded in Q2 2025.
- Aquestive Therapeutics' Operating Leases' 5-year high stood at $6.0 million during Q1 2023, with a 5-year trough of $1.9 million in Q4 2021.
- Moreover, its 3-year median value for Operating Leases was $5.6 million (2024), whereas its average is $5.5 million.
- As far as peak fluctuations go, Aquestive Therapeutics' Operating Leases tumbled by 31.62% in 2021, and later soared by 168.80% in 2023.
- Aquestive Therapeutics' Operating Leases (MRQ) stood at $1.9 million in 2021, then soared by 161.31% to $5.1 million in 2022, then rose by 6.18% to $5.4 million in 2023, then dropped by 7.98% to $5.0 million in 2024, then increased by 2.84% to $5.1 million in 2025.
- Its Operating Leases stands at $5.1 million for Q3 2025, versus $5.2 million for Q2 2025 and $5.4 million for Q1 2025.